Lovastatin controls signal transduction in vascular smooth muscle cells by modulating phosphorylation levels of mevalonate-independent pathways

Basic Research in Cardiology

Volumn 96, Issue 3, 2001, Pages 283-289

  Sindermann, Jürgen R ^a,b   Schmidt, Annette ^a   Breithardt, Günter ^a,b   Buddecke, Eckhart ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b INST OF REPRO MED OF THE UNIV   (Germany)

Author keywords

Lovastatin; Mitogen activated protein kinase; Phosphotyrosine; Ras; Vascular smooth muscle cells

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTYROSINE; PROTEIN P42; PROTEIN P44; RAS PROTEIN;

ANIMAL CELL; ARTERIOSCLEROSIS; ARTICLE; CATTLE; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG SPECIFICITY; ENZYME PHOSPHORYLATION; MODULATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; RESTENOSIS; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; CATTLE; CELL CULTURE TECHNIQUES; CORONARY VESSELS; LOVASTATIN; MEVALONIC ACID; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; RAS PROTEINS; RATS; SIGNAL TRANSDUCTION;

EID: 0035030772     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003950170059     Document Type: Article

References (36)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD 098059 is a specific inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7686-7689
2. Casscells W (1992) Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 86: 723-729
3. Cohen P (1997) The search for physiological substrates of the MAP and SAP kinases in mammalian cells. Trends Cell Biol 7: 353-361
4. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 101: 117-125
5. DeClue JE, Vass WC, Papageaorge AG, Lowy DR, Willumsen, BM (1991) Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51: 712-717
6. Farahi Far D, Peyron JF, Imbert V, Rossi B (1994) Immunofluorescent quantification of tyrosine phosphorylation of cellular proteins in whole cells by flow cytometry. Cytometry 15: 327-334
7. Flugelmann MY, Virmani R, Correa R, Yu Z-X, Farb A, Leon MB, Elami A, Fu Y-M, Casscells W, Epstein SE (1993) Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation 88: 2493-2500
8. Foegh ML, Virmani R (1993) Molecular biology of intimai proliferation. Curr Opin Cardiol 8: 938-950
9. Garrington TP, Johnson GL (1999) Organisation and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11: 211-218
10. Gordon D, Reidy MA, Benditt EP, Schwartz SM (1990) Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 87: 4600-4604
11. Grandaliano G, Biswas P, Choudhury GG, Abboud HE (1993) Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 44: 503-508
12. Indolfi C, Avvedimento EV, Rapacciuolo A, Esposito G, Di Lorenzo E, Leccia A, Pisani A, Chieffo A, Coppola A, Chiariello M (1997) In vivo gene transfer: prevention of neointima formation by inhibition of mitogen-activated protein kinase kinase. Bas Res Cardiol 92: 378-384
13. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z (1991) Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632
14. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI on behalf of the REGRESS Study Group (1995) Effects of lipid lowering by pravastatin on progression and regres-sion of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation 91: 2128-2540
15. Karim MA (1998) In vivo role of the extracellular matrix during vascular repair. Bas Res Cardiol 93: 50-54
16. Katsuda S, Coltrera MD, Ross R, Gown AM (1993) Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol 142: 1787-1793
17. Keyse SM (2000) Protein phosphatases and the regulation of mitogen-activated protein kinase signaling. Curr Opin Cell Biol 12: 186-192
18. Lawrence M, Watson L, Pettijohn T, Doyle T, Tasca SI, Stoica G (1995) Immunohistochemical localization of proliferating cells, basic fibroblast growth factor and Fos protein following iliac artery balloon angioplasty in hypercholesterolemic rabbits. In Vivo 9: 27-34
19. Lindner V, Reidy MA (1991) Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 88: 3739-3743
20. Maxwell SRJ (1998) Women and heart disease. Bas Res Cardiol 93: 79-84
21. McGuire TF, Corey SJ, Sebti SM (1993) Lovastatin inhibits platelet derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor. J Biol Chem 268: 22227-22230
22. McGuire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM (1994) Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. Biochem Biophys Res Commun 204: 399-406
23. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L (1992) Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 90: 1582-1592
24. Nikol S, Weir L, Sullivan A, Sharaf B, White CJ, Zemel G, Hartzler G, Stack R, Leclerc G, and Isner JM (1994) Persistently increased expression of the transforming growth factor-beta 1 gene in human vascular restenosis: analyis of 62 patients with one or more episodes of restenosis. Cardiovasc Pathol 3: 57-64
25. O'Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T, Simpson JB, Schwartz SM (1993) Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ Res 73: 223-231
26. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM (1993) Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 91: 1469-1480
27. Repko EM, Maltese WA (1989) Posttranslational isoprenylation of cellular proteins is altered in response to mevalonate availability. J Biol Chem 264: 9945-9952
28. Riessen R, Axel DI, Fenchel M, Herzog UU, Roßmann H, Karsch KR (1999) Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Bas Res Cardiol 94: 322-332
29. Rogler G, Lackner KJ, Schmitz G (1995) Mevalonate is essential for growth of porcine and human smooth muscle cells in vitro. Basic Res Cardiol 90: 443-450
30. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809
31. Scandinavian simvastatin survival study group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344: 1383-1389
32. Sindermann JR, Fan L, Weigel KA, Troyer D, Müller JG, Schmidt A, March KL, Breithardt G (2000) Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 150: 331-341
33. Sindermann J, Weigel KA, Breithardt G (1997) A simple method for the flow cytometric analysis of intracellular antigens in whole smooth muscle cells. Quantification of cyclin-dependent kinase 2. J Immunol Methods 202: 205-212
34. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillbower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487
35. Vincent TS, Wülfert E, Merler E (1991) Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophys Res Commun 180: 1284-1289
36. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, and the CCAIT study group (1994) Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian coronary atherosclerosis intervention trial. Circulation 89: 959-968